tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BIIB Stock Latest News

Biogen price target raised to $225 from $205 at Oppenheimer
The FlyBiogen price target raised to $225 from $205 at Oppenheimer
1d ago
BIIB
Biogen’s litifilimab receives FDA BTD for cutaneous lupus erythematosus
PremiumThe Fly
Biogen’s litifilimab receives FDA BTD for cutaneous lupus erythematosus
3d ago
BIIB
Acumen price target raised to $7 from $4 at BTIG
PremiumThe Fly
Acumen price target raised to $7 from $4 at BTIG
4d ago
ABOS
BIIB
Balancing Long‑Term Alzheimer’s Potential Against Near‑Term MS Headwinds: Rationale for Maintaining a Hold on Biogen
PremiumRatings
Balancing Long‑Term Alzheimer’s Potential Against Near‑Term MS Headwinds: Rationale for Maintaining a Hold on Biogen
4d ago
BIIB
Biogen price target raised to $185 from $180 at Citi
PremiumThe Fly
Biogen price target raised to $185 from $180 at Citi
4d ago
BIIB
Eisai, Biogen announces FDA accepted to review the sBLA for lecanemab-irmb
PremiumThe FlyEisai, Biogen announces FDA accepted to review the sBLA for lecanemab-irmb
5d ago
BIIB
Biogen sees Q4 pre-tax charge of $222M, or $1.26 per share
Premium
The Fly
Biogen sees Q4 pre-tax charge of $222M, or $1.26 per share
17d ago
BIIB
Balanced Risk/Reward Keeps Biogen at Hold Amid Slower Leqembi Upside, MS Erosion, and Uncertain Pipeline
Premium
Ratings
Balanced Risk/Reward Keeps Biogen at Hold Amid Slower Leqembi Upside, MS Erosion, and Uncertain Pipeline
18d ago
BIIB
Biogen Advances Presymptomatic SMA Strategy With New Salanersen Trial
PremiumCompany Announcements
Biogen Advances Presymptomatic SMA Strategy With New Salanersen Trial
19d ago
BIIB
Biogen announces EU approval for high dose regimen of Spinraza for SMA
PremiumThe Fly
Biogen announces EU approval for high dose regimen of Spinraza for SMA
19d ago
BIIB
Stoke Therapeutics updates timeline for Phase 3 EMPEROR study
PremiumThe Fly
Stoke Therapeutics updates timeline for Phase 3 EMPEROR study
20d ago
BIIB
STOK
Biogen Advances New SKYCLARYS Formulation in Early Trial, Supporting Long-Term Rare Disease Strategy
PremiumCompany Announcements
Biogen Advances New SKYCLARYS Formulation in Early Trial, Supporting Long-Term Rare Disease Strategy
22d ago
BIIB
Biogen price target raised to $190 from $142 at Truist
PremiumThe FlyBiogen price target raised to $190 from $142 at Truist
23d ago
BIIB
Biogen price target raised to $225 from $197 at Goldman Sachs
Premium
The Fly
Biogen price target raised to $225 from $197 at Goldman Sachs
23d ago
BIIB
Biogen price target raised to $207 from $177 at Mizuho
Premium
The Fly
Biogen price target raised to $207 from $177 at Mizuho
23d ago
BIIB
Biogen: Buy Rating Raised on Leqembi Commercial Momentum and 2026 Pipeline Catalysts
PremiumRatings
Biogen: Buy Rating Raised on Leqembi Commercial Momentum and 2026 Pipeline Catalysts
24d ago
BIIB
Biogen price target raised to $207 from $177 at Mizuho
PremiumThe Fly
Biogen price target raised to $207 from $177 at Mizuho
24d ago
BIIB
Biogen: Balanced Risk/Reward Amid Alzheimer’s and Autoimmune Pipeline Uncertainty Supports Hold Rating
PremiumRatings
Biogen: Balanced Risk/Reward Amid Alzheimer’s and Autoimmune Pipeline Uncertainty Supports Hold Rating
24d ago
BIIB
Biogen price target raised to $180 from $153 at Citi
PremiumThe Fly
Biogen price target raised to $180 from $153 at Citi
24d ago
BIIB
Biogen assumed with a Neutral at UBS
PremiumThe FlyBiogen assumed with a Neutral at UBS
25d ago
LLY
BIIB
Biogen, Eisai say Leqembi BLA accepted in China
Premium
The Fly
Biogen, Eisai say Leqembi BLA accepted in China
26d ago
BIIB
Biogen announces publication of long term results from Phase 3 VALOR study
Premium
The Fly
Biogen announces publication of long term results from Phase 3 VALOR study
1M ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >